Neeraj Agarwal

Summary

Affiliation: University of Utah
Country: USA

Publications

  1. ncbi request reprint Successful management of intra-abdominal hemorrhage in the presence of severe alcoholic liver disease with activated recombinant factor VII (rFVIIa; NovoSeven): a case report and review of the literature on approved and off-label use of rFVIIa
    Neeraj Agarwal
    Division of Hematology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah 84112, USA
    Blood Coagul Fibrinolysis 18:205-7. 2007
  2. doi request reprint Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments
    Tian Yi Zhang
    University of Utah, Huntsman Cancer Institute, 2000 Circle of Hope, Ste 2123, Salt Lake City, UT 84112, USA
    Curr Urol Rep 14:174-83. 2013
  3. ncbi request reprint A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors
    Hanna Bailey
    Huntsman Cancer Institute, The University of Utah, 2000 Circle of Hope, Ste 2123, Salt Lake City, UT, 84112, USA
    Cancer Chemother Pharmacol 78:1059-1071. 2016
  4. ncbi request reprint Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma (UC)
    Neeraj Agarwal
    University of Utah Huntsman Cancer Institute, Salt Lake City, UT Huntsman Cancer Institute, Salt Lake City, UT University of Utah, Salt Lake City, UT Cancer Research UK Institute for Cancer Studies, Birmingham, United Kingdom Massachusetts General Hospital, Boston, MA Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy Princess Margaret Hospital, Toronto, ON, Canada US Oncology Research, LLC, McKesson Specialty Health, The Woodlands, TX, and Tisch Cancer Institute, Mount Sinai Medical Center, New York, NY US Oncology Research, LLC, McKesson Specialty Health, The Woodlands, TX, and Deke Slayton Cancer Center, Webster, TX
    J Clin Oncol 30:308. 2012
  5. pmc Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong
    Rebecca A Campo
    Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
    J Cancer Surviv 8:60-9. 2014
  6. doi request reprint Inherited Variants in SULT1E1 and Response to Abiraterone Acetate by Men with Metastatic Castration Refractory Prostate Cancer
    Neeraj Agarwal
    Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah Electronic address
    J Urol 196:1112-6. 2016
  7. doi request reprint Development of novel immune interventions for prostate cancer
    Neeraj Agarwal
    Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
    Clin Genitourin Cancer 10:84-92. 2012
  8. doi request reprint A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin
    Neeraj Agarwal
    Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, 84112, UT, USA
    Cancer Chemother Pharmacol 77:299-308. 2016
  9. doi request reprint A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort
    Theresa L Werner
    Department of Medicine, Oncology Division, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA
    Invest New Drugs 33:1217-24. 2015
  10. doi request reprint Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma
    Benjamin L Maughan
    University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA
    Clin Genitourin Cancer 11:316-20. 2013

Collaborators

Detail Information

Publications22

  1. ncbi request reprint Successful management of intra-abdominal hemorrhage in the presence of severe alcoholic liver disease with activated recombinant factor VII (rFVIIa; NovoSeven): a case report and review of the literature on approved and off-label use of rFVIIa
    Neeraj Agarwal
    Division of Hematology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah 84112, USA
    Blood Coagul Fibrinolysis 18:205-7. 2007
    ..We review the current literature on the approved and off-label use of activated recombinant factor VII...
  2. doi request reprint Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments
    Tian Yi Zhang
    University of Utah, Huntsman Cancer Institute, 2000 Circle of Hope, Ste 2123, Salt Lake City, UT 84112, USA
    Curr Urol Rep 14:174-83. 2013
    ..We will also propose a strategy for optimal sequencing of these agents in the treatment of mCRPC...
  3. ncbi request reprint A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors
    Hanna Bailey
    Huntsman Cancer Institute, The University of Utah, 2000 Circle of Hope, Ste 2123, Salt Lake City, UT, 84112, USA
    Cancer Chemother Pharmacol 78:1059-1071. 2016
    ..Present data are lacking to provide dosing recommendations in renal insufficiency. The purpose of this trial was to assess the pharmacokinetics (PK) of belinostat and belinostat metabolites in plasma and urine...
  4. ncbi request reprint Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma (UC)
    Neeraj Agarwal
    University of Utah Huntsman Cancer Institute, Salt Lake City, UT Huntsman Cancer Institute, Salt Lake City, UT University of Utah, Salt Lake City, UT Cancer Research UK Institute for Cancer Studies, Birmingham, United Kingdom Massachusetts General Hospital, Boston, MA Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy Princess Margaret Hospital, Toronto, ON, Canada US Oncology Research, LLC, McKesson Specialty Health, The Woodlands, TX, and Tisch Cancer Institute, Mount Sinai Medical Center, New York, NY US Oncology Research, LLC, McKesson Specialty Health, The Woodlands, TX, and Deke Slayton Cancer Center, Webster, TX
    J Clin Oncol 30:308. 2012
    ..We pooled published phase II trials of GC and wGC to compare efficacy and safety...
  5. pmc Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong
    Rebecca A Campo
    Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
    J Cancer Surviv 8:60-9. 2014
    ..This 12-week randomized controlled trial examined the feasibility and efficacy of a Qigong intervention for improving older prostate cancer survivors' levels of fatigue and distress...
  6. doi request reprint Inherited Variants in SULT1E1 and Response to Abiraterone Acetate by Men with Metastatic Castration Refractory Prostate Cancer
    Neeraj Agarwal
    Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah Electronic address
    J Urol 196:1112-6. 2016
    ..The variations may serve as prognostic and predictive biomarkers to allow for more individualized therapy...
  7. doi request reprint Development of novel immune interventions for prostate cancer
    Neeraj Agarwal
    Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
    Clin Genitourin Cancer 10:84-92. 2012
    ....
  8. doi request reprint A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin
    Neeraj Agarwal
    Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, 84112, UT, USA
    Cancer Chemother Pharmacol 77:299-308. 2016
    ..The purpose of this study was to evaluate the pharmacokinetics and pharmacodynamics of warfarin (as a reference drug metabolized by CYP2C9) in the presence and absence of belinostat...
  9. doi request reprint A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort
    Theresa L Werner
    Department of Medicine, Oncology Division, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA
    Invest New Drugs 33:1217-24. 2015
    ..The novel mechanism of action of JI-101 is promising in ovarian cancer treatment and further prospective studies of this agent may be pursued in a less refractory patient population or in combination with cytotoxic chemotherapy...
  10. doi request reprint Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma
    Benjamin L Maughan
    University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA
    Clin Genitourin Cancer 11:316-20. 2013
    ..Weekly split-dose cisplatin with wGC might be less toxic and have similar activity, but has not been compared with GC. We pooled published phase II trials of GC and wGC to compare efficacy and safety...
  11. ncbi request reprint Management of cancer-associated thrombotic microangiopathy: what is the right approach?
    Theresa L Werner
    Division of Hematology, University of Utah Hospitals and Clinics, Salt Lake City, Utah, USA
    Am J Hematol 82:295-8. 2007
    ..Here we address one approach of management of these patients with cancer-associated TMA...
  12. doi request reprint Anemia of chronic disease (anemia of inflammation)
    Neeraj Agarwal
    Division of Hematology and Oncology, University of Utah School of Medicine and Veterans Affairs Hospital, Salt Lake City, Utah, USA
    Acta Haematol 122:103-8. 2009
    ..Successful treatment of the underlying disease improves ACD. If that is not possible and if anemia is symptomatic, treatment with erythropoietic agents, supplemented with iron if necessary, is helpful in many cases...
  13. pmc CYP17 inhibitors in prostate cancer: latest evidence and clinical potential
    Anitha B Alex
    Division of Medical Oncology, Department of Medicine, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA
    Ther Adv Med Oncol 8:267-75. 2016
    ..These include VT-464, orteronel, and galeterone. Herein, we focus on the molecular mechanism of action, efficacy, latest evidence, and clinical potential of CYP17 inhibitors in prostate cancer. ..
  14. pmc Immunotherapy of advanced renal cell carcinoma: Current and future therapies
    David Gill
    a Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA
    Hum Vaccin Immunother . 2016
    ..Either alone or in combination, these novel agents are encouraging for the future of mRCC therapy...
  15. pmc FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma
    Kevin P Horn
    Center for Quantitative Cancer Imaging, Huntsman Cancer Institute, University of Utah, 1950 Circle of Hope Dr, Suite 6810, Salt Lake City, UT, 84112 5560, USA
    Cancer Imaging 15:15. 2015
    ..In this exploratory study we sought to characterize early tumor response in patients with metastatic renal cell carcinoma treated with continuous daily 37.5 mg sunitinib therapy...
  16. pmc Identification of specific Y chromosomes associated with increased prostate cancer risk
    Lisa A Cannon-Albright
    Division of Genetic Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah George E Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah Huntsman Cancer Institute, Salt Lake City, Utah
    Prostate 74:991-8. 2014
    ..Evidence supports the possibility of a role of the Y chromosome in prostate cancer, but controversy exists...
  17. doi request reprint Management of hormone-sensitive metastatic prostate cancer
    Neeraj Agarwal
    Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Suite 2123, Salt Lake City, UT 84112, USA
    Hematol Oncol Clin North Am 27:1221-41, viii. 2013
    ....
  18. pmc Feasibility and acceptability of a Tai Chi Chih randomized controlled trial in senior female cancer survivors
    Rebecca A Campo
    University of Utah, Salt Lake City, UT, USA
    Integr Cancer Ther 12:464-74. 2013
    ....
  19. doi request reprint Novel molecular targets for the therapy of castration-resistant prostate cancer
    Neeraj Agarwal
    Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
    Eur Urol 61:950-60. 2012
    ....
  20. pmc Methylation of AR locus does not always reflect X chromosome inactivation state
    Sabina I Swierczek
    Department of Medicine, Division of Hematology, University of Utah School of Medicine Salt Lake City, UT 84132, USA
    Blood 119:e100-9. 2012
    ..These data provide the molecular basis of incomplete correlation with the pattern of DNA methylation of this X chromosome AR gene locus...
  21. pmc Erythropoietic agents and the elderly
    Neeraj Agarwal
    Hematology and Oncology, Department of Internal Medicine, University of Utah School of Medicine and Veterans Administration Hospital, Salt Lake City, UT, USA
    Semin Hematol 45:267-75. 2008
    ....
  22. ncbi request reprint Acquired amegakaryocytic thrombocytopenic purpura
    Neeraj Agarwal
    Division of Hematology, Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah 84132, USA
    Am J Hematol 81:132-5. 2006
    ..We report a case that responded to treatment with cyclosporine but not to IL-11. The bone marrow biopsy, repeated after resolution of thrombocytopenia, showed normal number of megakaryocytes...